BARDA backs Atox drug to combat zombie-like bacteria
This article was originally published in Scrip
Israeli firm Atox Bio has won a contract potentially worth $23.9m from the US Biomedical Advanced Research and Development Authority (BARDA) to advance the development of the company's AB103, an investigational drug aimed at combating zombie-like “flesh-eating” bacteria and potential biothreats.
You may also be interested in...
Private Company Edition: Polaris is raising up to $400m for its next tech and health care fund, following in the footsteps of several life science investors this year. Also, Nevakar raises $50m in a product financing agreement and RAPT closes a $37m series C extension.
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.